Commentary Open Access
Volume 3 | Issue 1 | DOI: https://doi.org/10.33696/immunology.3.074
The Role of Quantification of Glucocorticoid-associated Toxicity in Severe Asthma
PJ McDowell1, JH Stone2, LG Heaney1,*
- 1Centre for Experimental Medicine, School of Medicine, Dentistry, and Biological Sciences; Queen’s University Belfast, Northern Ireland, UK
- 2Division of Rheumatology, Allergy, & Clinical Immunology, Massachusetts General Hospital,Harvard Medical School, USA
Corresponding Author
Liam Heaney, l.heaney@qub.ac.uk
Received Date: October 26, 2020
Accepted Date: January 18, 2021
McDowell1 PJ, Stone JH, Heaney LG. The Role of Quantification of Glucocorticoid-associated Toxicity in Severe Asthma. J Cell Immunol. 2021; 3(1): 31-35.
Copyright: © 2021 McDowell PJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
Severe asthma, Glucocorticoid toxicity index (GTI)
Recommended Articles
Diet and Exercise: A Novel Cure for Asthma? - A Short Communications on a Non-Pharmacological Strategy
Behavioral interventions with regular physical activity, weight loss and diet have repeatedly demonstrated preventive effects in a wide range of diseases. Furthermore, an unhealthy lifestyle is a known predictor for increased use of medication and also the leading risk factor for global mortality.
The Role of Quantification of Glucocorticoid-associated Toxicity in Severe Asthma
Until recently, oral glucocorticoid (GC) therapies were the mainstay of treatment for uncontrolled inflammatory disease across many body systems. The last 30 years, however, have witnessed a transformation in the management of many diseases due to the development of targeted biological agents leading to a reduction, albeit not a removal, of the dependence on oral GCs.